In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Mobile cardiopaging in toxic cardiomyopathy diagnostics in cancer patients

Session Poster Session 4

Speaker Nadezda Lyamina

Event : Heart Failure 2018

  • Topic : heart failure
  • Sub-topic : Cardiotoxicity of Drugs and Other Therapies
  • Session type : Poster Session

Authors : N Lyamina (Saratov,RU), S Lyamina (Moscow,RU), E Kotelnikova (Saratov,RU), V Senchikhin (Saratov,RU), T Lipchanskaya (Saratov,RU)

Authors:
N Lyamina1 , S Lyamina2 , E Kotelnikova1 , V Senchikhin1 , T Lipchanskaya1 , 1Research Institute of Cardiology Saratov State Medical University named after V.I. Razumovskiy - Saratov - Russian Federation , 2Moscow State University of Medicine and Dentistry named after A.I. Evdokimov - Moscow - Russian Federation ,

Citation:

Background: The use of modern high-efficient cancer chemotherapy treatment in 5-35% of cases is accompanied by cardiotoxic effect varying from asymptomatic electrocardiography (ECG) changes to the development of acute coronary syndrome (ACS) and heart failure (CHF) that significantly impair the patients’ life expectancy.

Purpose: Assessment of the feasibility of cardiopaging using due to improve the effectiveness of cardiotoxic effect diagnostics in cancer patients.

Methods: Remote management effectiveness was assessed in cardio-oncological patients with heart failure (CHF) (22 patients: 12 men, 10 women, 52.6±5.5 y.o., NYHA 2.04±0.25, ejection fraction 48.6±6.5%). Patients were included in the study from 2 to 12 months after the chemotherapy start with 6 months follow-up period. Cardiopaging was performed on the principle of autotransmitting mobile devices and Internet application ECG Dongle. Asynchronous telecardiologic platform "CardioCloud" was used for information storage and analysis, telemedicine counseling. In CHF/chemotherapy group standard therapy was administered considering the patients’ clinical status. ECG was registered 5 times a week. ECG was registered in addition in the case of any clinical symptoms present or according to the patients’ desire. ECG registration duration was 10-20 minutes. ECG data were analyzed by an external doctor (an employee of the Cardiology Research Institute). Analysed data included mean heart rate, any rhythm or conduction disorders, dynamics of ST changes, QT duration. If necessary, medication was prescribed.

Results. Within 6 months not previously documented ECG changes were remotely registered in all CHF/chemotherapy patients. Among them sinus tachycardia was predominant (88%). Against the background of sinus tachycardia ventricular extrasystole of various gradations (38%), supraventricular extrasystole (24%), transient tachy-dependent bundle-branch blockages (9%) were registered. Atrial fibrillation paroxysms were observed in 2 patients. In 55% of patients complicated ECG disorders were registered in the form of sinus tachycardia and supraventricular rhythm disorders (extrasystole, episodes of atrial fibrillation) combination, and sinus tachycardia, ventricular extrasystole and ST depression. The majority pf detected violations were symptomatic (65%), in other cases patients did not complain. Within the framework of office counseling 7 (70%) patients had arterial hypertension (AH) of I-III degree. ß-blockers and ACE inhibitors were prescribed to correct the identified violations and AH.

Conclusions. Remote dynamic management of cancer patients with chemotherapy including ECG registration (=5 times/week, 10-20 min) on the base of mobile cardiopaging combined with doctors’ counseling is a sufficiently effective and accessible method of cardiotoxicity phenomenon diagnostics. The main advantage of the method is the possibility of early pharmacological correction in asymptomatic cardiovascular disorders.

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are